CClinicalTrials.gg
RecruitingNCT06043726DAGPEUpdated Sep 21, 2023

Diagnostic Accuracy of Arterial-alveolar Oxygen Gradient in Low Risk Patients With Suspected Pulmonary Embolism

An observational study in Pulmonary Embolism, sponsored by Franciscus Gasthuis. Recruiting at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Franciscus Gasthuis · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
230
Sex
All
01

Study summary

Introduction:

The diagnosis of pulmonary embolism (PE) is a challenge in the Emergency Department. D-dimer based diagnostic algorithms for PE have a very high sensitivity, but rely upon a vast amount of CT angiography and potentially unnecessary exposure to radiation. An accurate diagnostic algorithm that does not involve d-dimer testing might reduce this burden.

An abnormal Alveolar-arterial oxygen gradient (A-a gradient) seems to increase the chance of PE. However, a normal A-a gradient on its own does not exclude the diagnosis. In this paper, the accuracy of A-a gradient testing and a combination of Years criteria with A-a gradient testing will be assessed.

Methods:

This is a prospective, single center, observational study. All patients that present at our emergency department from September 2022 until September 2023 with a suspicion of pulmonary embolism will be analyzed for eligibility and included in the study after informed consent. The aim is to include at least 230 patients in the study.

Analysis: The primary outcome is the diagnostic accuracy of a YEARS and A-a gradient based algorithm for pulmonary embolism. The secondary outcome is the potential decrease in performed imaging in order to exclude pulmonary embolism.

Valorisation An accurate A-a gradient-based algorithm for pulmonary embolism in low risk patients will be a step towards an improved clinical risk score. We aim to reduce the amount of diagnostic imaging, i.e. CT-angiography. Meaning less, potentially unnecessary, exposure to radiation for the patient. Furthermore, it could lower healthcare costs by reducing expensive diagnostic imaging.

02

Conditions studied

  • Pulmonary Embolism

Keywords

  • A-a gradient
03

In context

Pulmonary Embolism

739 studies on the registry are indexed under Pulmonary Embolism; 158 are open to participants now.

This study's planned enrollment of 230 is below the median of 383 across 323 observational studies indexed under Pulmonary Embolism.

Browse Pulmonary Embolism studies →

Lead sponsor

Franciscus Gasthuis is the lead sponsor of 18 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients that present in our emergency department with suspicion of pulmonary embolism

Inclusion criteria

  • Patient with suspected pulmonary embolism
  • Emergency department D-dimer result available
  • Arterial blood gas available

Exclusion criteria

Exclusion Criteria:

  • Patients without documented oxygen suppletion durig blood gas measurement
  • Patients without documented and insufficient data to calculate YEARS criteria
  • Pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
230 participants (estimated)
Patient registry
No

Groups and cohorts

  • Suspected PE

    Patients with suspected pulmonary embolism

    Diagnostic Test: Laboratory testing: D-dimeer and astrup

Interventions

  • Diagnostic testLaboratory testing: D-dimeer and astrup

    Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated

    Also known as: CT-scan for pulmonary embolism

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of a combination of a normal Alveolar-Arterial Oxygen Gradient with negative YEARS criteria in patients with suspected pumonary embolism

    Time frame: At submission in the Emergency Department

Secondary outcomes

  1. How many CT-scans would have been avoided if the algorithm was used in normal practice

    Time frame: At submission in the Emergency Department

07

Study locations

1 of 1 sites recruiting
  • Franciscus Gasthuis
    Rotterdam, Netherlands
    • Sander Mol · Contact · +31104616161
    • Rick Thissen · Principal investigator
    • Sophie Nieuwendijk · Principal investigator
    • Renee Deckers · Principal investigator
    Recruiting
08

References and documents

Publications

  • van der Hulle T, Cheung WY, Kooij S, Beenen LFM, van Bemmel T, van Es J, Faber LM, Hazelaar GM, Heringhaus C, Hofstee H, Hovens MMC, Kaasjager KAH, van Klink RCJ, Kruip MJHA, Loeffen RF, Mairuhu ATA, Middeldorp S, Nijkeuter M, van der Pol LM, Schol-Gelok S, Ten Wolde M, Klok FA, Huisman MV; YEARS study group. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017 Jul 15;390(10091):289-297. doi: 10.1016/S0140-6736(17)30885-1. Epub 2017 May 23. Erratum In: Lancet. 2017 Jul 15;390(10091):230. doi: 10.1016/S0140-6736(17)31749-X. PubMed 28549662 ↗
  • Kline JA, Courtney DM, Kabrhel C, Moore CL, Smithline HA, Plewa MC, Richman PB, O'Neil BJ, Nordenholz K. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008 May;6(5):772-80. doi: 10.1111/j.1538-7836.2008.02944.x. Epub 2008 Mar 3. PubMed 18318689 ↗
  • McFarlane MJ, Imperiale TF. Use of the alveolar-arterial oxygen gradient in the diagnosis of pulmonary embolism. Am J Med. 1994 Jan;96(1):57-62. doi: 10.1016/0002-9343(94)90116-3. PubMed 8304364 ↗
  • Stein PD, Goldhaber SZ, Henry JW. Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. Chest. 1995 Jan;107(1):139-43. doi: 10.1378/chest.107.1.139. PubMed 7632205 ↗
  • Powrie RO, Larson L, Rosene-Montella K, Abarca M, Barbour L, Trujillo N. Alveolar-arterial oxygen gradient in acute pulmonary embolism in pregnancy. Am J Obstet Gynecol. 1998 Feb;178(2):394-6. doi: 10.1016/s0002-9378(98)80031-8. Erratum In: Am J Obstet Gynecol 1999 Aug;181(2):510. PubMed 9500505 ↗
  • Masotti L, Ceccarelli E, Cappelli R, Barabesi L, Forconi S. Arterial blood gas analysis and alveolar-arterial oxygen gradient in diagnosis and prognosis of elderly patients with suspected pulmonary embolism. J Gerontol A Biol Sci Med Sci. 2000 Dec;55(12):M761-4. doi: 10.1093/gerona/55.12.m761. PubMed 11129400 ↗
  • Overton DT, Bocka JJ. The alveolar-arterial oxygen gradient in patients with documented pulmonary embolism. Arch Intern Med. 1988 Jul;148(7):1617-9. PubMed 3132902 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06043726
Lead sponsor
Franciscus Gasthuis
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 1, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 21, 2023

Study contacts

Rick Thissen
Contact
r.thissen@franciscus.nl
+3110 461 6161
Sophie Nieuwendijk
Contact
Sander Mol
study chair · Franciscus Gasthuis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion